A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastoma
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Cancer"
DOI: 10.1002/ijc.33044
Abstract: Neuroblastoma is a sympathetic nervous system tumor, primarily presenting in children under 6 years of age. The long‐term prognosis for patients with high‐risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapy. This report provides an update… read more here.
Keywords: therapy; dfmo maintenance; phase trial;